CLPT — what changed in the latest 10-Q
A section-by-section comparison of CLPT's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-10-28 vs the prior 10-Q · 2026-08-03
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +12 | −13 | ~32 | 29 |
| Market risk (Item 3) | No paragraph-level changes | 0 | 0 | 0 | 1 |
| Controls & procedures | Text added/removed | 0 | 0 | ~2 | 0 |
| Legal proceedings | No paragraph-level changes | 0 | 0 | 0 | 1 |
| Risk factors | Some risk factors updated | +5 | −1 | ~4 | 2 |
| Other information | Text added/removed | +1 | −1 | ~2 | 0 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-10-28
In 2021, we started providing consulting services to our pharmaceutical and other medical technology customers for improving outcome predictability and optimizing preclinical and clinical workflows. Our expertise is concentrated in benchtop testing, preclinical studies, clinical trial support, regul…
Our neurosurgery navigation and therapy revenue primarily consists of disposable product commercial sales related to cases utilizing the ClearPoint and IRRAflow systems. Generating recurring revenue from the sale of disposable products is an important part of our business model. Future revenue from …
Our biologics and drug delivery revenue comes from sales of products, including disposable products, and services related to customer-sponsored preclinical and clinical trials utilizing our products. Our biologics and drug delivery customers are pharmaceutical and biotech companies, academic institu…
technological platforms internationally, (iv) invest in the IRRAflow product portfolio and clinical evidence, and (v) develop robotics and focused ultrasound technologies.
Revenue. Total revenue was $12.1 million for the three months ended September 30, 2026, and $8.9 million for the three months ended September 30, 2025, which represents an increase of $3.2 million, or 36%.
Text removed vs the prior filing · source: 10-Q · 2026-08-03
In 2021, we started providing consulting services to our pharmaceutical and other medical technology customers for improving outcome predictability and optimizing preclinical and clinical workflows. Our expertise is concentrated in
benchtop testing, preclinical studies, clinical trial support, regulatory consultation, and over-arching translation from the preclinical to the clinical setting to enhance accuracy and precision of drug delivery.
Our neurosurgery navigation and therapy revenue primarily consists of disposable product commercial sales related to cases utilizing the ClearPoint and IRRAflow systems. Generating recurring revenue from the sale of disposable products is an important part of our business model. Future revenue from …
Our biologics and drug delivery revenue comes from sales of products, including disposable products, and services related to customer-sponsored preclinical and clinical trials utilizing our products. Our biologics and drug delivery customers are pharmaceutical and biotech companies, academic institu…
and development costs may increase as we: (i) develop devices and services for delivery of therapeutics into the central nervous system, (ii) expand products into the operating room and therapeutics space, (iii) expand the application of our technological platforms internationally, (iv) invest in th…
Risk factors
Text added vs the prior filing · source: 10-Q · 2026-10-28
may lose all or part of your investment. There have been no material changes to the risk factors disclosed under Part I, Item 1A. "Risk Factors" in our 2025 Form 10-K, other than the risks discussed below:
Establishing and operating our preclinical CRO facility (CAL) is capital intensive and subject to significant execution risk, and we may not realize the anticipated benefits of this investment. Our facility leases also impose significant long-term fixed obligations.
In addition, we may require additional space, whether at the facility or elsewhere, and we may rely from time to time on temporary or short-term arrangements to perform certain services, whether on an interim or ongoing basis. Such arrangements may be limited in duration, depend on the consent or co…
the lease for the CAL facility has an initial term that expires approximately eleven years after the last portion of the premises was delivered to us with the landlord's improvements substantially complete, and our rent obligations under the lease, which are subject to annual increases, are fixed re…
More generally, we lease our corporate headquarters and our manufacturing, laboratory, and office facilities under non-cancelable operating leases with fixed, multi-year payment obligations. We may be unable to renew these leases on acceptable terms or to sublease or exit space we no longer need, an…
Text removed vs the prior filing · source: 10-Q · 2026-08-03
Establishing and operating our preclinical CRO facility (CAL) is capital intensive and subject to significant execution risk, and we may not realize the anticipated benefits of this investment.
Other information
Text added vs the prior filing · source: 10-Q · 2026-10-28
On August 18, 2026, Danilo D'Alessandro, our Chief Financial Officer, adopted a new Rule 10b5-1 trading arrangement intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). The trading arrangement expires November 30, 2027, subject to earlier expiration if all transactions thereunde…
Text removed vs the prior filing · source: 10-Q · 2026-08-03
On June 4, 2026, Lynnette C. Fallon, a member of our Board of Directors, adopted a new Rule 10b5-1 trading arrangement intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). The plan's maximum duration is until December 31, 2027. The maximum number of shares to be sold under the p…
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice